Welcome to our dedicated page for Stem SEC filings (Ticker: STEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to separate Athena software revenue from battery hardware sales in Stem Inc’s disclosures? You’re not alone. Stem’s hybrid model packs performance obligations, supply-chain risks, and grid-service bid data into hundreds of pages—making each 10-K annual report a tough read.
Stock Titan delivers the solution. Our AI decodes every Stem annual report 10-K simplified, flags the note that explains contracted backlog, and highlights how management recognizes revenue on hardware vs SaaS. Prefer quarter-to-quarter trends? The Stem quarterly earnings report 10-Q filing arrives in real time, with instant ratio analysis and plain-English summaries so you can act before the call ends.
Need alerts on executive behavior? Track Stem insider trading Form 4 transactions—and receive push notifications when Stem Form 4 insider transactions real-time disclose new stock grants or sales. Material announcements? Our engine tags each Stem 8-K material events explained entry and shows what it means for project pipelines.
- AI-powered summaries turn technical language into actionable insight
- Real-time EDGAR feeds for every filing type, from S-8 to 424B
- Side-by-side comparison tools for Stem earnings report filing analysis
Whether you’re understanding Stem SEC documents with AI, reviewing the Stem proxy statement executive compensation, or monitoring Stem executive stock transactions Form 4, Stock Titan condenses the data you need into minutes, not hours.
Brian Musfeldt, Chief Financial Officer of STEM, Inc. (STEM), amended a Form 4 to report equity awards granted on 07/17/2025. The amendment discloses 2,500 RSUs that vest 100% on 08/07/2027, 6,750 PSUs that vest upon meeting a volume-weighted average price target over any consecutive 60 trading-day period, and 1,250 stock options with an exercise price of $9.27 that expire on 07/17/2035 and vest 100% on 08/07/2027. The amended filing corrects omissions and an earlier miscount: the original Form 4 omitted the RSUs and options and reported 5,500 PSUs instead of 6,750 PSUs. All reported awards are listed as direct holdings.
STEM, Inc. filing a Form 144 reports a proposed sale of 134 shares of common stock, with an aggregate market value of $2,670.49, to be sold on or about 10/02/2025 on the NYSE. The shares were acquired by the seller on 09/26/2025 through restricted stock vesting and were received as compensation. The filing lists 8,359,047 shares outstanding for the class. The filer reports no sales of the issuer's securities by the seller in the past three months and includes the standard signer representation that they are not aware of undisclosed material adverse information about the issuer.
Stem, Inc. registers for resale up to 439,919 warrants and up to 439,919 common shares issuable upon exercise of those warrants, issued June 30, 2025, as part of exchanges of its 2028 and 2030 convertible notes. Each warrant is exercisable for one share at $30.00 per share and expires at close of business on December 1, 2030. Stem's common stock trades on the NYSE under STEM; the last reported sale price on September 8, 2025 was $13.50. The prospectus warns of potential dilution, limited warrant liquidity, and directs readers to incorporated SEC filings for risks and financial details.
Stem, Inc. files an S-3 shelf registration describing resale of Common Stock and Warrants held by selling securityholders. The document incorporates by reference Stem's 2024 Form 10-K (filed March 5, 2025), Quarterly Reports on Form 10-Q for periods ended March 31, 2025 and June 30, 2025 (filed April 30 and August 8, 2025), and multiple Form 8-Ks.
The company has authorized 250,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock. As of August 31, 2025 there were 8,387,658 shares of Common Stock outstanding and 439,919 Warrants outstanding. Each Warrant is exercisable for one share at $30.00 per share and expires December 1, 2030. Warrants include anti-dilution adjustments and other customary terms. Deloitte & Touche LLP audited Stem’s consolidated financial statements for years through December 31, 2024.
Brian Musfeldt, Chief Financial Officer of Stem, Inc. (STEM), received equity awards on 07/17/2025 totaling 22,000 underlying shares. The grants consist of 11,000 restricted stock units (RSUs) vesting in three nearly equal annual installments beginning August 7, 2026; 5,500 performance stock units (PSUs) that vest only if a 60-trading-day volume-weighted average price target is met; and 5,500 stock options with a $9.27 exercise price, exercisable through July 17, 2035 and vesting in the same three-installment schedule beginning August 7, 2026. Each RSU and PSU represents the contingent right to one share of common stock. Following these grants, Mr. Musfeldt beneficially owns 22,000 shares subject to these awards. The Form 4 was submitted by an attorney-in-fact on 08/19/2025.
This Form 144 is a Rule 144 notice reporting a proposed sale of common stock by a person who acquired the shares through restricted stock vesting. The filer plans to sell 5,951 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $81,203.78. The filing lists 8,359,047 shares outstanding. The securities were acquired on 08/07/2025 by Restricted Stock Vesting from the issuer and the stated nature of payment is compensation. The approximate date of sale is 08/11/2025. The notice also reports Nothing to Report for securities sold in the past three months and includes the standard signer representation about material adverse information.
FAQ
What is the current stock price of Stem (STEM)?
What is the market cap of Stem (STEM)?
